Long-Term Efficacy of Adjunctive Cariprazine in Patients With MDD: Results From an Open-Label 26-Week Safety Study

被引：0
|
作者：
Masand, Prakash [1 ]
Vieta, Eduard [1 ]
Waraich, Simranpreet [1 ]
Kramer, Ken [1 ]
Kerolous, Majid [1 ]
机构：
[1] AbbVie, New York, NY USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2023年 / 48卷
关键词：
Cariprazine; Major Depressive Disorder; Depression; Adjunctive; Long-Term;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
P343
引用
收藏
页码：263 / 264
页数：2
相关论文
共 50 条
  • [21] Long-term safety and efficacy of brivaracetam in adults with focal seizures: Results from an open-label, multinational, follow-up trial
    Arnold, Stephan
    Laloyaux, Cedric
    Schulz, Anne-Liv
    Elmoufti, Sami
    Yates, Stephen
    Fakhoury, Toufic
    EPILEPSY RESEARCH, 2020, 166
  • [22] A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia
    Forbes, Andy
    Hobart, Mary
    Ouyang, John
    Shi, Lily
    Pfister, Stephanie
    Hakala, Mika
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2018, 21 (05) : 433 - 441
  • [23] Long-term Safety of Rivastigmine in Parkinson Disease Dementia: An Open-Label, Randomized Study
    Emre, Murat
    Poewe, Werner
    De Deyn, Peter Paul
    Barone, Paolo
    Kulisevsky, Jaime
    Pourcher, Emmanuelle
    van Laar, Teus
    Storch, Alexander
    Micheli, Federico
    Burn, David
    Durif, Frank
    Pahwa, Rajesh
    Callegari, Francesca
    Tenenbaum, Nadia
    Strohmaier, Christine
    CLINICAL NEUROPHARMACOLOGY, 2014, 37 (01) : 9 - 16
  • [24] Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study
    Filts, Yuriy
    Litman, Robert E.
    Martinez, Javier
    Anta, Lourdes
    Naber, Dieter
    Correll, Christoph U.
    SCHIZOPHRENIA RESEARCH, 2022, 239 : 83 - 91
  • [25] An open-label extension long-term study of the safety and efficacy of aripiprazole for irritability in children and adolescents with autistic disorder in Japan
    Ichikawa, Hironobu
    Hiratani, Michio
    Yasuhara, Akihiro
    Tsujii, Noa
    Oshimo, Takashi
    Ono, Hiroaki
    Tadori, Yoshihiro
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2018, 72 (02) : 84 - 94
  • [26] Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study
    Deleuran, Mette
    Thaci, Diamant
    Beck, Lisa A.
    de Bruin-Weller, Marjolein
    Blauvelt, Andrew
    Forman, Seth
    Bissonnette, Robert
    Reich, Kristian
    Soong, Weily
    Hussain, Iftikhar
    Foley, Peter
    Hide, Michihiro
    Bouaziz, Jean-David
    Gelfand, Joel M.
    Sher, Lawrence
    Schuttelaar, Marie L. A.
    Wang, Chen
    Chen, Zhen
    Akinlade, Bolanle
    Gadkari, Abhijit
    Eckert, Laurent
    Davis, John D.
    Rajadhyaksha, Manoj
    Staudinger, Heribert
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Ardeleanu, Marius
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (02) : 377 - 388
  • [27] The Efficacy, Safety, and Tolerability of Probiotics on Depression: Clinical Results From an Open-Label Pilot Study
    Wallace, Caroline J. K.
    Milev, Roumen V.
    FRONTIERS IN PSYCHIATRY, 2021, 12
  • [28] Long-Term Safety, Tolerability, and Durability of Treatment Effect of Olanzapine and Samidorphan: Results of a 4-Year Open-Label Study
    Ballon, Jacob S.
    Kahn, Rene S.
    Arevalo, Christina
    Dunbar, Martin
    Mcdonnell, David
    Correll, Christoph U.
    JOURNAL OF CLINICAL PSYCHIATRY, 2025, 86 (01)
  • [29] A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression
    Soczynska, Joanna K.
    Kennedy, Sidney H.
    Alsuwaidan, Mohammad
    Mansur, Rodrigo B.
    Li, Madeline
    McAndrews, Mary Pat
    Brietzke, Elisa
    Woldeyohannes, Hanna O.
    Taylor, Valerie H.
    McIntyre, Roger S.
    BIPOLAR DISORDERS, 2017, 19 (03) : 198 - 213
  • [30] Long-term safety and efficacy of bilastine following up to 12 weeks or 52 weeks of treatment in Japanese patients with allergic rhinitis: Results of an open-label trial
    Okubo, Kimihiro
    Gotoh, Minoru
    Togawa, Michinori
    Saito, Akihiro
    Ohashi, Yoshihiro
    AURIS NASUS LARYNX, 2017, 44 (03) : 294 - 301
12345